10-KPeriod: FY2020

BIOGEN INC. Annual Report, Year Ended Dec 31, 2020

Filed February 3, 2021For Securities:BIIB

Summary

Biogen Inc.'s 2020 10-K filing reveals a challenging year marked by revenue decline, primarily driven by increased competition for its flagship multiple sclerosis (MS) drug, TECFIDERA, which faced generic entrants. Total revenues decreased by 6.5% to $13.44 billion, with product revenues down 6.0% to $10.69 billion. This was partially offset by growth in its biosimilar business and other revenue streams. Despite the revenue dip, Biogen significantly increased its R&D spending by 75.0% to $3.99 billion, largely due to substantial upfront payments for new collaborations in Alzheimer's, Parkinson's, and other neurological disorders. The company is also awaiting a crucial FDA decision on aducanumab for Alzheimer's disease, which, if approved, could be a significant growth driver. Financially, Biogen ended 2020 with approximately $3.38 billion in cash, cash equivalents, and marketable securities. The company repurchased approximately $6.7 billion of its stock in 2020, signaling a commitment to shareholder returns. Looking ahead, Biogen faces ongoing competition in its core MS market and anticipates continued pressure on TECFIDERA sales due to generics. The company is actively investing in its pipeline through strategic partnerships and aiming for new therapeutic breakthroughs, particularly in Alzheimer's and other neurodegenerative diseases, which represent key areas for future growth and value creation.

Financial Highlights

55 data points
Beta

Revenue

$13.44B

86.6% Gross Margin

Net Income

$4.00B

29.8% Net Margin

EPS (Diluted)

$24.80

Total Assets

$24.62B

Cash & Equivalents

$1.33B

Free Cash Flow

$3.81B

Financial Statements
Beta
Revenue$13.44B
Cost of Revenue$1.81B
Gross Profit$11.64B
SG&A Expenses$2.50B
Operating Expenses$8.40B
Operating Income$4.55B
Interest Expense$222.50M
Net Income$4.00B
EPS (Basic)$24.86
EPS (Diluted)$24.80
Shares Outstanding (Basic)160.90M
Shares Outstanding (Diluted)161.30M

Key Highlights

  • 1Total revenues for 2020 decreased by 6.5% to $13.44 billion, primarily due to a 8.2% decline in MS product revenues, driven by generic competition for TECFIDERA.
  • 2Research and Development (R&D) expenses surged by 75.0% to $3.99 billion, largely attributed to significant upfront payments for new collaborations in neurological disease areas.
  • 3The company is awaiting a critical FDA decision on aducanumab for Alzheimer's disease, with the PDUFA date extended to June 7, 2021.
  • 4Biogen repurchased approximately $6.7 billion of its common stock in 2020 under various repurchase programs.
  • 5SPINRAZA, the company's spinal muscular atrophy treatment, saw a 2.1% decrease in revenues in 2020, facing increased competition.
  • 6The biosimilar business showed growth, with revenues increasing by 7.8% in 2020.
  • 7As of December 31, 2020, Biogen held approximately $3.38 billion in cash, cash equivalents, and marketable securities.

Frequently Asked Questions

In 2020, Biogen experienced a challenging financial year with total revenues decreasing by 6.5% to $13.44 billion. Product revenues, net, fell by 6.0% to $10.69 billion, primarily due to increased generic competition for TECFIDERA and a decline in interferon-based MS treatments. However, the company significantly ramped up its R&D spending by 75% to $3.99 billion, driven by strategic collaborations.

Biogen completed the submission of its Biologics License Application (BLA) for aducanumab for Alzheimer's disease in July 2020. The FDA granted Priority Review, with the PDUFA action date extended to June 7, 2021. The potential approval of aducanumab is a key event for Biogen, as it represents a significant opportunity in a large, underserved market, despite mixed advisory committee feedback.

Biogen is actively investing in its pipeline to drive future growth, as evidenced by the substantial increase in R&D spending. This includes significant upfront payments for new collaborations focused on neurological and neurodegenerative diseases with companies like Sage Therapeutics, Denali Therapeutics, and Sangamo Therapeutics. The company is also expanding its biosimilar portfolio and has secured rights to potential ophthalmology biosimilars.

Biogen faces several key risks, including ongoing generic competition for TECFIDERA, which has already impacted revenues and is expected to continue to do so. Competition in the multiple sclerosis market remains intense, and the company is also subject to pricing pressures and regulatory scrutiny. The success of its pipeline, particularly the aducanumab filing, is critical for future growth. Additionally, the ongoing COVID-19 pandemic continues to present uncertainties regarding demand, clinical trial operations, and supply chains.